Soleus Capital Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 11, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Soleus Capital Management reported a $2.9 bn portfolio of 96 companies (97 positions, counting each share class separately) to the SEC as of the end of Q2 2026. Its largest positions are KRYS, CELC, TGTX. During the quarter it opened Erasca.
Sections with a free account
What changed this quarter
100 positions with a change (19 new, 23 added to, 41 trimmed, 17 sold); also, 2 entered through an IPO. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedParabilis MedicinesPBLS1.4% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Krystal Biotech−19%fewer sharesReduced12.1% → 12.0%
- Insulet+86%more sharesIncreased4.8% → 5.5%
- Rigel Pharmaceuticals+18,335%more sharesIncreasedunder 0.1% → 2.5%
- TG Therapeutics−27%fewer sharesReduced5.4% → 5.5%
- Inspire Medical Systems+235%more sharesIncreased1.2% → 3.0%
- Twist Bioscience−91%fewer sharesReduced2.4% → 0.4%
- Praxis Precision Medicines−46%fewer sharesReduced4.3% → 2.0%
- Erasca+1.7 ppof portfolioNew— → 1.7%
- Alkermes plc.−48%fewer sharesReduced2.8% → 1.9%
- Vericel−43%fewer sharesReduced3.3% → 2.2%
- Celcuity+33%more sharesIncreased5.9% → 6.1%
- Edgewise Therapeutics−69%fewer sharesReduced1.8% → 0.6%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Krystal BiotechKRYS12.0%
- CelcuityCELC6.1%
- TG TherapeuticsTGTX5.5%
- InsuletPODD5.5%
- NovoCureNVCR5.2%
- United TherapeuticsUTHR4.2%
- Inspire Medical SystemsINSP3.0%
- Rigel PharmaceuticalsRIGL2.5%
- ANI PharmaceuticalsANIP2.5%
- Beta BionicsBBNX2.4%
- Indivior PharmaceuticalsINDV · SUPN2.3%
- VericelVCEL2.2%
- Praxis Precision MedicinesPRAX2.0%
- GeronGERN1.9%
- Alkermes plc.ALKS1.9%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 97
Q2 2026: 49%
Q2 2026: 27.5%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- BIT Capital GmbHInvestment firm · $2.9 bn
- Caledonia (Private) Investments PtyInvestment firm · $2.9 bn
- James Hambro & Partners LLPInvestment firm · $2.9 bn
- Palestra Capital ManagementInvestment firm · $2.9 bn
- Hardman Johnston Global AdvisorsInvestment firm · $2.9 bn
- Westwood Global InvestmentsInvestment firm · $2.8 bn